Compare American Tower Corp (AMT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Novartis AG — how do they compare? American Tower Corp trades at $170 (market cap $78.80B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 3.8× American Tower Corp's market cap, and American Tower Corp pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| AMT | NVS | |
|---|---|---|
Market Cap | $78.80B | $298.18B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $168.62 |
52-Week Low | $162.11 | $119.31 |
Enterprise Value | $122.32B | $339.50B |
Dividend Yield | 4.13% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $172.54, up 0.78% on the day, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.86 exceeding the $1.57 forecast. Revenue for 2025 reached $10.64 billion, with a robust net income margin of 26.81%. Analyst sentiment is overwhelmingly positive, with 39 of 49 analysts rating it a Buy and a consensus price target of $206.17, implying significant upside. Recent news highlights insider selling and upbeat analyst coverage.
The outlook for AMT is favorable, driven by resilient telecom demand, 5G/6G expansion, and double-digit growth in its data center segment. Key risks include sensitivity to interest rates, Dish Network churn impacts, and high debt levels. With strong cash flow from operations and a bullish analyst consensus, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic factors warrant monitoring.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
